Q1 2026 Holdings
Filed 2026-05-15 | 75 holdings | $2.6B | 13F-HR | View on SEC ↗ · Holdings Table ↗
Sign in to see sub-manager breakdown
| Issuer | Class | CUSIP | Value ↑ | Shares | % Portfolio |
|---|---|---|---|---|---|
| Ideaya Biosciences Inc(IDYA) | COM | 45166A102 | $37.7M | 1,131,786 | 1.4% |
| Arrivent BioPharma Inc(AVBP) | COM | 04272N102 | $39.1M | 1,696,752 | 1.5% |
| Rhythm Pharmaceuticals Inc(RYTM) | COM | 76243J105 | $39.1M | 450,096 | 1.5% |
| BioAge Labs Inc(BIOA) | COM | 09077V100 | $40.1M | 2,293,788 | 1.5% |
| Celcuity Inc(CELC) | COM | 15102K100 | $41.8M | 366,175 | 1.6% |
| Biogen Inc(BIIB) | COM | 09062X103 | $42.1M | 229,521 | 1.6% |
| BioMarin Pharmaceutical Inc(BMRN) | COM | 09061G101 | $44.2M | 781,982 | 1.7% |
| United Therapeutics Corp(UTHR)Put | COM | 91307C102 | $47.6M | 80,300 | 1.8% |
| Supernus Pharmaceuticals(SUPN) | COM | 868459108 | $49.3M | 954,309 | 1.9% |
| Alcon AG(ALC) | ORD SHS | H01301128 | $55.0M | 729,972 | 2.1% |
| Insmed Inc(INSM) | COM PAR $.01 | 457669307 | $56.6M | 346,075 | 2.2% |
| Rapport Therapeutics Inc(RAPP) | COM | 75383L102 | $59.6M | 1,904,408 | 2.3% |
| Ultragenyx Pharmaceutical Inc(RARE) | COM | 90400D108 | $65.9M | 3,145,888 | 2.5% |
| iShares TR(IBB)Put | ISHARES BIOTECH | 464287556 | $80.2M | 475,000 | 3.0% |
| Cogent Biosciences Inc(COGT) | COM | 19240Q201 | $81.4M | 2,113,551 | 3.1% |
| Invesco QQQ TR(QQQ)Put | UNIT SER 1 | 46090E103 | $86.6M | 150,000 | 3.3% |
| AstraZeneca PLC(AZN) | ORD | G0593M107 | $89.9M | 456,031 | 3.4% |
| United Therapeutics Corp(UTHR) | COM | 91307C102 | $94.9M | 160,070 | 3.6% |
| Vera Therapeutics Inc(VERA) | CL A | 92337R101 | $112.4M | 2,793,987 | 4.3% |
| Jazz Pharmaceuticals PLC(JAZZ) | SHS USD | G50871105 | $113.1M | 598,327 | 4.3% |
| Bristol-Myers Squibb Co(BMY) | COM | 110122108 | $120.6M | 1,988,721 | 4.6% |
| Spdr Series Trust(XBI)Put | STATE STREET SPD | 78464A870 | $134.1M | 1,050,000 | 5.1% |
| iShares TR(IWM)Put | RUSSELL 2000 ETF | 464287655 | $148.8M | 600,000 | 5.7% |
| Natera Inc(NTRA) | COM | 632307104 | $310.0M | 1,550,280 | 11.8% |